



ANI Pharmaceuticals announces the launch of ANI Global Source, its contract development and manufacturing business

October 29, 2019

BAUDETTE, Minnesota (October 29, 2019) – ANI Pharmaceuticals, Inc. (“ANI”) (Nasdaq: ANIP), an experienced specialty pharmaceutical and contract development & manufacturing organization (CDMO), today announced the launch of its new CDMO brand, ANI Global Source. This action follows the integration of WellSpring Pharma Services, acquired one year ago, and demonstrates the progress the company has made since the acquisition. ANI Global Source is a specialty CDMO supporting late stage development and commercial manufacture of pharmaceutical products including tablets & capsules, liquid solutions, suspensions, topical liquids, creams and gels with unique expertise in hormones, potent compounds, and controlled substances. ANI Global Source will continue to leverage its robust infrastructure including over 300 employees and 270,000 square feet of manufacturing and packaging facilities across multiple sites.

The launch of ANI Global Source will be highlighted by a new website (www.aniglobalsource.com), logo, visual identity, and series of brand communications culminating in a strong presence as an exhibitor and sponsor of the CPhI Worldwide conference, November 5-7, 2019 in Frankfurt, Germany. We look forward to introducing ANI Global Source at CPhI Worldwide, and we believe it truly represents our commitment and track record for on-time delivery, exemplary quality, exceptional project management, and broad scientific expertise.

ANI Global Source will be located at Booth #121H63 during the CPhI Worldwide event.

Contact: Russell Miller
Senior Director, Contract Sales
Russell.miller@anipharmaceuticals.com
919-407-1530

About ANI Global Source

ANI Global Source is a world-leading specialty CDMO dedicated to supporting late stage development and commercial manufacture of pharmaceutical products. With over 60 years of experience and a 270,000 ft² manufacturing and packaging footprint, ANI Global Source’s multiple sites deliver on a wide range of pharmaceutical manufacturing needs, including tablets & capsules (coated/uncoated), liquid solutions, suspensions, topical liquids, creams and gels. Additionally, the company offers unique expertise in manufacture of hormones, potent compounds, and DEA Class II controlled substances. Beyond the company’s manufacturing capabilities, though, is a demonstrated track record and ongoing commitment to exemplary quality, on-time delivery, proactive project management and a customer-centric approach to clear and effective communication. Through the strong collaborative relationships we have developed with clients, ANI Global Source is a preferred partner that continues to deliver consistent supply for patients.

MAbout ANI

ANI Pharmaceuticals, Inc. (the “Company” or “ANI”) is an integrated specialty pharmaceutical company developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company’s targeted areas of product development currently include narcotics, oncolytics (anti-cancers), hormones and steroids, and complex formulations involving extended release and combination products. For more information, please visit our website www.anipharmaceuticals.com.

Forward-Looking Statements

To the extent any statements made in this release deal with information that is not historical, these are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about price increases, the Company's future operations, products, financial position, operating results and prospects, the Company's pipeline or potential markets therefor, and other statements that are not historical in nature, particularly those that utilize terminology such as "anticipates," "will," "expects," "plans," "potential," "future," "believes," "intends," "continue," other words of similar meaning, derivations of such words and the use of future dates.

Uncertainties and risks may cause the Company's actual results to be materially different than those expressed in or implied by such forward-looking statements. Uncertainties and risks include, but are not limited to, the risk that the Company may face with respect to importing raw materials; increased competition; acquisitions; contract manufacturing arrangements; delays or failure in obtaining product approval from the U.S. Food and Drug Administration; general business and economic conditions; market trends; products development; regulatory and other approvals and marketing.

More detailed information on these and additional factors that could affect the Company's actual results are described in the Company's filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as its proxy statement. All forward-looking statements in this news release speak only as of the date of this news release and are based on the Company's current beliefs, assumptions, and expectations. The Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

For more information about ANI, please contact:
Investor Relations
IR@anipharma.com